The U.S. Point-of-Care Diagnostics Market is expected to reach $13.16 billion by 2030, at a CAGR of 4.3% during the forecast period 2023–2030. Point-of-care diagnostics, or bedside tests, are diagnostic tests performed on-site by healthcare professionals. These tests provide quick and accurate results without requiring samples to be sent to a laboratory. Point-of-care diagnostics products quickly determine a marker responsible for a certain disease. These tests can be used in various point-of-care settings such as physician offices, urgent care facilities, long-term care facilities, and nursing homes. Also, these devices can be categorized as handheld, transportable, and portable based on format.
The U.S. point-of-care diagnostics market is growing due to innovation in POC tests, growing commercialization of CLIA-waived POC tests, increasing funding for research and development, rising awareness regarding early disease diagnosis, and increasing prevalence of chronic and infectious diseases. However, stringent regulatory policies and pricing pressure due to fluctuations in reimbursements are restraining the growth of this market. Furthermore, growing investments in healthcare infrastructure and healthcare professionals' increasing preference for POC tests over other lab tests across the U.S. are expected to offer significant growth opportunities in the market. In addition, a lack of awareness regarding the use of POC devices is a major challenge to the market’s growth.
In efforts to deliver effective diagnostic products, key market players are focused on simplifying and automating disease diagnosis and detection steps, revolutionizing disease diagnosis processes. For instance, manufacturers have started developing automated platforms that require minimal hands-on time by trained laboratory personnel; this has driven a shift in diagnostic testing from centralized laboratories to near-patient settings, such as hospital labs, physicians’ offices, hospital outpatient departments, and home healthcare facilities. CLIA-waived tests enable testing in point-of-care settings. These tests are simple procedures with an insignificant risk of erroneous results. Such tests can be used in several settings, including pharmacy-based clinics, urgent care centers, and hospitals. Waived tests that can be performed in physician offices include streptococcus testing, HIV testing, INR (coagulation) testing for Coumadin, and pregnancy testing. CLIA-waived tests speed up diagnosis and treatment, improving patients’ clinical outcomes.
Furthermore, CLIA-waived PoC tests bring high diagnostic sensitivity and specificity to point-of-care testing. If a test is CLIA-waived, the site or facility performing the assay does not need to document personnel qualifications and training, perform quality control procedures (unless specified in the test instructions), or conduct proficiency testing or routine quality assessment related to that assay. Thus, by securing CLIA grants, vendors can help customers by reducing the documentation burden.
Click here to: Get Free Sample Pages of this Report
Healthcare Professionals’ Increasing Preference for PoC Tests Over Other Lab Tests Creates an Opportunity for Market Growth
Many healthcare professionals in hospitals and clinical laboratories prefer using point-of-care diagnostics to diagnose several health conditions promptly. Healthcare professionals are replacing established diagnostic methods (microscopy, pathogen culturing, biochemical testing, conventional polymerase chain reaction (PCR), enzyme-linked immunoassay (ELISA), and other time-consuming diagnostic methods) with new point-of-care diagnostic techniques that provide higher levels of efficiency and reproducibility. The advantages of point-of-care diagnostics include faster turnaround times, convenience, cost-effectiveness, improved patient outcomes, and patient satisfaction. Point-of-care diagnostic tests deliver rapid results, whereas traditional lab tests can take days to provide results. This speed can be crucial for time-sensitive medical conditions, allowing healthcare providers to make timely decisions about patient care.
Further, PoC tests are performed on-site, eliminating the need to send samples to a laboratory. This saves time and resources and can be particularly useful for patients who live in remote or rural areas. These tests are less expensive than traditional lab tests, requiring less equipment and personnel, making them a more affordable option for healthcare providers, particularly in resource-constrained settings. PoC tests help healthcare providers make faster and more accurate diagnoses, which can lead to improved patient outcomes. For example, PoC tests for infectious diseases can help healthcare providers quickly identify and treat patients, preventing the spread of diseases. Thus, the inclination towards point-of-care methods and medical practices among physicians drives the growth of the U.S. point-of-care diagnostics market.
The Consumables Segment is Expected to Dominate the U.S. Point-of-Care Diagnostics Market in 2023
Among all the offerings, in 2023, the consumables segment is expected to account for the largest share of the market. Factors such as the growing demand for rapid diagnosis, the commercial availability of a diverse range of consumables, several product launches and approvals from the key players, increasing demand for POC diagnostics kits owing to their benefits such as ease of use, portability, and accuracy are contributing to the large share of this segment. PoC diagnostic kits are pre-packaged sets of materials and reagents for performing tests. These diagnostic kits are user-friendly, with clear instructions for use, and require minimal training, making them ideal for use in settings with limited access to trained laboratory personnel, such as rural or remote areas.
The Molecular Diagnostics Platform Segment is Expected to Register the Highest CAGR During the Forecast Period
Among all the platforms, the molecular diagnostics segment is projected to register the highest CAGR during the forecast period. Molecular diagnostics is a sensitive method that enables the detection of lower amounts of infectious agents. Molecular tests are designed to detect the genetic material of a virus, bacteria, or other pathogens in a patient's sample, such as blood or saliva. Factors such as relative ease of use, high sensitivity, specificity, and accuracy of molecular tests, ability to perform rapid analysis, the widening applications of molecular detection tests in various fields, and high popularity and awareness regarding RT-PCR diagnostics tests are driving the segment’s growth.
The Blood Glucose Monitoring Segment is Expected to Dominate the U.S. Point-of-Care Diagnostics Market in 2023
Among all the applications, in 2023, the blood glucose monitoring segment is expected to account for the largest share of the market. The large market share of this segment is mainly attributed to the increased prevalence of diabetes and the need for glucose monitoring devices. For instance, as per data from the International Diabetes Federation’s (IDF) Diabetes Atlas, nearly 32,215.3 adults in the U.S. survived with diabetes in 2021. This number is expected to reach 34,755.3 by 2030 and 36,289.9 by 2045.
The Blood Sample Type Segment is Expected to Dominate the U.S. Point-of-Care Diagnostics Market in 2023
Among all the sample types, in 2023, the blood sample type segment is expected to account for the largest share of the market. The large share of this segment is attributed to the availability of a wide range of tests that can be conducted using blood samples and an increasing awareness among consumers about the importance of self-monitoring. Blood samples are ideal for multiple point-of-care testing for diagnosing chronic diseases. Owing to the increasing prevalence of chronic and infectious diseases, early diagnosis is critical for successful treatment and prevention. For instance, in 2021, an estimated 32,100 new HIV infections occurred in the U.S.
The Home Care/Self-Testing Segment is Expected to Account for the Largest Share of the U.S. Point-of-Care Diagnostics Market
Among all the end users, in 2023, the home care/self-testing segment is expected to account for the largest share of the U.S. point-of-care diagnostics market. The largest share of the segment is attributed to the increasing prevalence of chronic diseases requiring long-term care and frequent monitoring, increasing home healthcare spending, growing awareness about home care, and the increasing availability of user-friendly and advanced POC diagnostic products. Also, the elderly population is more likely to have comorbidities and prefer staying in their home surroundings, leading to increasing demand for home care settings across the U.S.
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in the industry over the years. The key players profiled in the U.S. point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), QuidelOrtho Corporation (U.S.), Sekisui Diagnostics, LLC. (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), and Nova Biomedical (U.S.).
Report Summary:
|
Particular |
Details |
|
Page No |
200 |
|
Format |
|
|
Forecast Period |
2023-2030 |
|
Base Year |
2022 |
|
CAGR |
4.3% |
|
Market Size (Value) |
$13.16 billion |
|
Market Size (Volume) |
Units |
|
Segments Covered |
Offering, Platform, Technique, Sample Type, and End User |
|
Countries Covered |
U.S. |
|
Key Companies |
Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), QuidelOrtho Corporation (U.S.), Sekisui Diagnostics, LLC. (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), and Nova Biomedical (U.S.). |
Scope of the Report:
U.S. Point-of-Care Diagnostics Market Assessment, by Offering
U.S. Point-of-Care Diagnostics Market Assessment, by Platform
U.S. Point-of-Care Diagnostics Market Assessment, by Applications
U.S. Point-of-Care Diagnostics Market Assessment, by Sample Type
U.S. Point-of-Care Diagnostics Market Assessment, by End User
Key questions answered in the report:
The U.S. point-of-care diagnostics market study covers the market sizes & forecasts for various point-of-care diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the point-of-care diagnostics market at the country level.
The U.S. point-of-care diagnostics market is projected to reach $13.16 billion by 2030, at a CAGR of 4.3% during the forecast period.
The consumables segment is expected to account for the largest share of the market in 2023. Factors such as the benefits offered by point-of-care diagnostics kits, such as ease of use, portability, and accuracy. POC diagnostic kits are pre-packaged sets of materials and reagents for performing tests. These diagnostic kits are user-friendly, with clear instructions for use, and require minimal training, making them ideal for use in settings with limited access to trained laboratory personnel, such as rural or remote areas, which are contributing the largest share of this segment.
In 2023, the lateral flow assays segment is estimated to hold the major share, owing to factors such as their one-step process, long shelf life, higher portability & lower costs compared to laboratory-based tests, low sample quantities required for testing, recent technological developments, and the increasing use of lateral flow assay kits that can be used at home.
The blood sample segment is projected to create more traction during the forecast period due to the availability of a wide range of tests that can be conducted using blood samples, the growing prevalence of chronic diseases, and an increasing awareness among consumers about the importance of self-monitoring.
The growing CLIA-waived POC tests, increasing funding for research and development, innovation in POC tests, rising awareness regarding early disease diagnosis, and increasing prevalence of chronic diseases coupled with the aging population are the key factors driving the U.S. point of care diagnostics market. Furthermore, growing investments in healthcare infrastructure and healthcare professionals' increasing preference for POC tests over other lab tests across the U.S. are expected to offer significant growth opportunities in the market.
The key players profiled in the U.S. point-of-care diagnostics market Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), QuidelOrtho Corporation (U.S.), Sekisui Diagnostics, LLC. (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), and Nova Biomedical (U.S.).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing & Forecast
2.3.1. Market Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for This Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Innovations in POC Tests
4.2.2. Growing Commercialization of CLIA-Waived POC Tests
4.2.3. Increasing Funding for Research and Development
4.2.4. Rising Awareness Regarding Early Disease Diagnosis
4.2.5. Increasing Prevalence of Chronic and Infectious Diseases
4.3. Restraints
4.3.1. Stringent Regulatory Policies
4.3.2. Pricing Pressure Due to Fluctuations in Reimbursements
4.4. Opportunity
4.4.1. Growing Investments in Healthcare Infrastructure
4.4.2. Healthcare Professionals’ Increasing Preference for POC Tests Over Other Lab Tests
4.5. Challenges
4.5.1. Lack of Awareness Regarding the Use of POC Devices
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Industry and Technology Trends
5. U.S. Point-of-Care Diagnostics Market Assessment, by Offering
5.1. Overview
5.2. Consumables
5.3. Instruments
5.4. Software and Services
6. U.S. Point-of-Care Diagnostics Market Assessment, by Platform
6.1. Overview
6.2. Lateral Flow Assays
6.3. Molecular Diagnostics
6.4. Other Platforms
7. U.S. Point-of-Care Diagnostics Market Assessment, by Applications
7.1. Overview
7.2. Blood Glucose Monitoring
7.3. Infectious Disease Testing
7.3.1. Parasitic Infections Testing
7.3.2. Blood-borne Infections Testing
7.3.2.1. Hepatitis
7.3.2.2. HIV
7.3.2.3. Other Blood-borne Infections Testing
7.3.3. Respiratory Infections Testing
7.3.3.1. Influenza
7.3.3.2. Pneumonia
7.3.3.3. Tuberculosis (TB)
7.3.3.4. COVID-19 Testing
7.3.3.5. Other Respiratory Infections Testing
7.3.4. Healthcare-associated Infections (HAI) Testing
7.3.5. Gastrointestinal Infections Testing
7.3.5.1. Salmonellosis
7.3.5.2. E. Coli Infections
7.3.5.3. Other GI Infections Testing
7.3.6. Other Infectious Diseases Testing
7.4. Tumor/Cancer Markers Testing
7.5. Pregnancy And Fertility Testing
7.5.1. Pregnancy Testing
7.5.2. Fertility Testing
7.6. Cardiac Marker/Cardiac Metabolism Testing
7.7. Cholesterol/Lipid Profile Testing
7.8. Coagulation Testing
7.8.1. Prothrombin Time (PT/INR) Testing
7.8.2. Activated Clotting Time (ACT/APTT) Testing
7.8.3. Other Coagulation Testing
7.9. Hematology
7.10. Drugs of Abuse Testing
7.11. Urinalysis
7.12. Other POC Diagnostic Testing
8. U.S. Point-of-Care Diagnostics Market Assessment, by Sample Type
8.1. Overview
8.2. Blood Sample
8.3. Nasopharyngeal Swab
8.4. Urine Sample
8.5. Saliva Sample
8.6. Other Sample Types
9. U.S. Point-of-Care Diagnostics Market Assessment—by End User
9.1. Overview
9.2. Hospitals
9.3. Home Care/Self-testing
9.4. Physician Offices & Ambulatory Care Settings
9.5. Diagnostic Laboratories
9.6. Other End Users
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis, by the Key Player/Key Market Ranking, 2022
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Abbott Laboratories
11.2. F. Hoffmann-La Roche Ltd
11.3. Siemens Healthineers AG
11.4. Danaher Corporation
11.5. Thermo Fisher Scientific Inc.
11.6. Becton, Dickinson and Company (BD)
11.7. bioMérieux S.A.
11.8. QuidelOrtho Corporation
11.9. EKF Diagnostics Holdings plc
11.10. Sekisui Diagnostics, LLC.
11.11 Trinity Biotech plc
11.12. Chembio Diagnostics, Inc.
11.13. Werfen
11.14. Nova Biomedical
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 U.S. Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 2 U.S. Point-of-Care Diagnostics Consumables Market, 2021–2030 (USD Million)
Table 3 U.S. Point-of-Care Diagnostics Instruments Market, 2021–2030 (USD Million)
Table 4 U.S. Point-of-Care Diagnostics Market for Software and Services, 2021–2030 (USD Million)
Table 5 U.S. Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 6 U.S. Point-of-Care Diagnostics Market for Lateral Flow Assays, 2021–2030 (USD Million)
Table 7 U.S. Point-of-Care Diagnostics Market for Molecular Diagnostics, 2021–2030 (USD Million)
Table 8 U.S. Point-of-Care Diagnostics Market for Other Platforms, 2021–2030 (USD Million)
Table 9 U.S. Point-of-Care Diagnostics Market, by Application, 2021–2030
Table 10 U.S. Point-of-Care Diagnostics Market for Blood Glucose Monitoring, 2021–2030 (USD Million)
Table 11 U.S. Point-of-Care Diagnostics Market for Infectious Diseases Testing, by Type, 2021–2030 (USD Million)
Table 12 U.S. Point-of-Care Diagnostics Market for Infectious Diseases Testing, 2021–2030 (USD Million)
Table 13 U.S. Point-of-Care Diagnostics Market for Parasitic Infections Testing, 2021–2030 (USD Million)
Table 14 U.S. Point-of-Care Diagnostics Market for Blood-borne Infections Testing, by Type, 2021–2030 (USD Million)
Table 15 U.S. Point-of-Care Diagnostics Market for Blood-borne Infections Testing, 2021–2030 (USD Million)
Table 16 U.S. Point-of-Care Diagnostics Market for Hepatitis, 2021–2030 (USD Million)
Table 17 U.S. Point-of-Care Diagnostics Market for HIV, 2021–2030 (USD Million)
Table 18 U.S. Point-of-Care Diagnostics Market for Other Blood-borne Infections, 2021–2030 (USD Million)
Table 19 U.S. Point-of-Care Diagnostics Market for Respiratory Infections Testing, by Type, 2021–2030 (USD Million)
Table 20 U.S. Point-of-Care Diagnostics Market for Respiratory Infections Testing, 2021–2030 (USD Million)
Table 21 U.S. Point-of-Care Diagnostics Market for Influenza, 2021–2030 (USD Million)
Table 22 U.S. Point-of-Care Diagnostics Market for Pneumonia, 2021–2030 (USD Million)
Table 23 U.S. Point-of-Care Diagnostics Market for Tuberculosis, 2021–2030 (USD Million)
Table 24 U.S. Point-of-Care Diagnostics Market for COVID-19 Testing, 2021–2030 (USD Million)
Table 25 U.S. Point-of-Care Diagnostics Market for Other Respiratory Infections Testing, 2021–2030 (USD Million)
Table 26 U.S. Point-of-Care Diagnostics Market for Healthcare-associated Infection (HAI) Testing, 2021–2030 (USD Million)
Table 27 U.S. Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, by Type, 2021–2030 (USD Million)
Table 28 U.S. Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, 2021–2030 (USD Million)
Table 29 U.S. Point-of-Care Diagnostics Market for Salmonellosis, 2021–2030 (USD Million)
Table 30 U.S. Point-of-Care Diagnostics Market for E. Coli Infections, 2021–2030 (USD Million)
Table 31 U.S. Point-of-Care Diagnostics Market for Other GI Infections, 2021–2030 (USD Million)
Table 32 U.S. Point-of-Care Diagnostics Market for Other Infectious Diseases Testing, 2021–2030 (USD Million)
Table 33 U.S. Point-of-Care Diagnostics Market for Tumor/Cancer Markers Testing, 2021–2030 (USD Million)
Table 34 U.S. Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, by Type, 2021–2030 (USD Million)
Table 35 U.S. Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, 2021–2030 (USD Million)
Table 36 U.S. Point-of-Care Diagnostics Market for Pregnancy Testing, 2021–2030 (USD Million)
Table 37 U.S. Point-of-Care Diagnostics Market for Fertility Testing, 2021–2030 (USD Million)
Table 38 U.S. Point-of-Care Diagnostics Market for Cardiac Marker/Cardiac Metabolism Testing, 2021–2030 (USD Million)
Table 39 U.S. Point-of-Care Diagnostics Market for Cholesterol/Lipid Profile Testing, 2021–2030 (USD Million)
Table 40 U.S. Point-of-Care Diagnostics Market for Coagulation Testing, by Type, 2021–2030 (USD Million)
Table 41 U.S. Point-of-Care Diagnostics Market for Coagulation Testing, 2021–2030 (USD Million)
Table 42 U.S. Point-of-Care Diagnostics Market for Prothrombin Time (PT/INR) Testing, 2021–2030 (USD Million)
Table 43 U.S. Point-of-Care Diagnostics Market for Activated Clotting Time (ACT/APTT) Testing, 2021–2030 (USD Million)
Table 44 U.S. Point-of-Care Diagnostics Market for Other Coagulation Testing, 2021–2030 (USD Million)
Table 45 U.S. Point-of-Care Diagnostics Market for Hematology, 2021–2030 (USD Million)
Table 46 U.S. Point-of-Care Diagnostics Market for Drugs of Abuse Testing, 2021–2030 (USD Million)
Table 47 U.S. Point-of-Care Diagnostics Market for Urinalysis, 2021–2030 (USD Million)
Table 48 U.S. Point-of-Care Diagnostics Market for Other PoC Testing, 2021–2030 (USD Million)
Table 49 U.S. Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 50 U.S. Point-of-Care Diagnostics Market for Blood Sample, 2021–2030 (USD Million)
Table 51 U.S. Point-of-Care Diagnostics Market for Nasopharyngeal Swab, 2021–2030 (USD Million)
Table 52 U.S. Point-of-Care Diagnostics Market for Urine Sample, 2021–2030 (USD Million)
Table 53 U.S. Point-of-Care Diagnostics Market for Saliva Sample, 2021–2030 (USD Million)
Table 54 U.S. Point-of-Care Diagnostics Market for Other Sample Types, by Country, 2021–2030 (USD Million)
Table 55 U.S. Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 56 U.S. Point-of-Care Diagnostics Market for Hospitals, 2021–2030 (USD Million)
Table 57 U.S. Point-of-Care Diagnostics Market for Home Care/Self-testing, 2021–2030 (USD Million)
Table 58 U.S. Point-of-Care Diagnostics Market for Physician Offices & Ambulatory Care Settings, 2021–2030 (USD Million)
Table 59 U.S. Point-of-Care Diagnostics Market for Diagnostic Laboratories, 2021–2030 (USD Million)
Table 60 U.S. Point-of-Care Diagnostics Market for Other End Users, 2021–2030 (USD Million)
Table 61 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 U.S. Point-of-Care Diagnostics Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 8 U.S. Point-of-Care Diagnostics Market, by Platform, 2023 Vs. 2030 (USD Million)
Figure 9 U.S. Point-of-Care Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 U.S. Point-of-Care Diagnostics Market, by Sample Type, 2023 Vs. 2030 (USD Million)
Figure 11 U.S. Point-of-Care Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 12 Market Dynamics: U.S. Point-of-Care Diagnostics Market
Figure 13 U.S. Point-of-Care Diagnostics Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 14 U.S. Point-of-Care Diagnostics Market, by Platform, 2023 Vs. 2030 (USD Million)
Figure 15 U.S. Point-of-Care Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 16 U.S. Point-of-Care Diagnostics Market, by Sample Type, 2023 Vs. 2030 (USD Million)
Figure 17 U.S. Point-of-Care Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 18 U.S. Point-of-Care Diagnostics Market Snapshot
Figure 19 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 20 U.S. Point-of-Care Diagnostics Market: Competitive Benchmarking, by Type
Figure 21 U.S. Point-of-Care Diagnostics Market: Competitive Dashboard
Figure 22 U.S. Point-of-Care Diagnostics Market: Market Share Analysis (2022)
Figure 23 Abbott laboratories: Financial Snapshot, 2022
Figure 24 F. Hoffmann-La Roche Ltd: Financial Snapshot, 2022
Figure 25 Siemens Healthineers AG: Financial Snapshot, 2022
Figure 26 Danaher Corporation: Financial Snapshot, 2022
Figure 27 Thermo Fisher Scientific Inc.: Financial Snapshot 2022
Figure 28 Becton, Dickinson and Company: Financial Snapshot, 2022
Figure 29 bioMérieux S.A.: Financial Snapshot, 2022
Figure 30 QuidelOrtho Corporation: Financial Snapshot, 2022
Figure 31 EKF Diagnostics Holdings plc: Financial Snapshot, 2022
Figure 32 Sekisui Chemical Co., Ltd.: Financial Snapshot, 2022
Figure 33 Trinity Biotech plc: Financial Snapshot, 2022
Figure 34 Chembio Diagnostics: Financial Snapshot, 2022
Figure 35 Werfen: Financial Snapshot, 2022
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2024
Published Date: Jan-2024
Published Date: Sep-2023
Published Date: Aug-2023
